PA122 CD254 / TNFSF11 / TRANCE antigen
see all 39 CD254 / TNFSF11 / TRANCE products
2 µg / US$ 255
NOVUS BIOLOGICALS
PO Box 802 Littleton, CO 80160, USA
E-Mail: novus@novus-biologicals.com
Homepage: http://www.novus-biologicals.com
PO Box 802 Littleton, CO 80160, USA
E-Mail: novus@novus-biologicals.com
Homepage: http://www.novus-biologicals.com
Quick Overview
Human CD254 / TNFSF11 / TRANCE
Synonyms
TNFSF11, OPGL, RANKL, TRANCE, , Receptor activator of nuclear factor kappa B ligand, TNF-related activation-induced cytokine, Tumor necrosis factor ligand superfamily member 11
Product Description
Human CD254 / TNFSF11 / TRANCE
Properties
| Species | Human |
| Purity | >97% |
| Source | E. coli |
| Molecular Weight | 20 kD |
| Catalog Number | PA122 |
| Swiss Prot. No. | O14788 |
| Quantity | 2 µg |
| Price | US$ 255 |
| Delivery | Worldwide |
| Manufacturer | Acris Antibodies GmbH |
| Datasheet | view  PA122.pdf |
Datasheet Extract
| Alternate names | TNFSF11, TRANCE (TNF-related activation-induced cytokine), OPGL, ODF (Osteoclast differentiation factor)
|
| Background | RANKL and RANK are members of the TNF superfamily of ligands and receptors that play an important role in the regulation of specific immunity and bone turnover. RANK (receptor) was originally identified as a dendritic-cell-membrane protein, which by interacting with RANKL augments the ability of dendritic cells to stimulate naïve T-cell proliferation in a mixed lymphocyte reaction, to promote the survival of RANK + T cells, and to regulate T-cell-dependent immune response. RANKL, which is expressed in a variety of cells including osteoblasts, fibroblasts, activated T-cells and bone marrow stromal cells, is also capable of interacting with a decoy receptor called OPG. Binding of soluble OPG to sRANKL inhibits osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells, thereby leading to excess accumulation of bone and cartilage. |
| Immunogen | Swiss Num.: O14788 |
| Source | E. coli |
| Format | State: Sterile filtered, lyophilized Purity: > 98% pure by SDS-PAGE and HPLC analyses BufferSystem: 5 mM Sodium Phosphate, pH 7.6 + 75 mM NaCl Endotoxinlevel: < 0.1 ng per µg (1EU/µg) Reconstitution: Centrifuge the vial prior to opening. Restore in water to a concentration of 0.1-1.0 mg/ml. This solution can then be diluted into other aqueous buffers and stored at 2-8°C for 1 week or at -20°C for future use. |
| Description | Recombinant human sRANKL is a polypeptide comprising the TNF homologous region of RANKL (176 amino acid residues). AASequence: MEKAMVDGSW LDLAKRSKLE AQPFAHLTIN ATDIPSGSHK VSLSSWYHDR GWAKISNMTF SNGKLIVNQD GFYYLYANIC FRHHETSGDL ATEYLQLMVY VTKTSIKIPS SHTLMKGGST KYWSGNSEFH FYSINVGGFF KLRSGEEISI EVSNPSLLDP DQDATYFGAF KVRDID Biological Activity: Assay 1: Determined by its ability to induce osteoclast formation in RAW264.7 cells using a concentration range of 5.0-10.0 ng/ml. Assay 2: The ED50 as determined by the dose-dependent stimulation of IL-8 production in human PBMCs is < / = 10 ng/ml. Molecular weight: 20.0 kDa |
| Storage | The lyophilized protein is stable at -20°C for one year from date of despatch.
Reconstituted sRANKL is stable for 3 months when stored in working aliquots with a carrier protein at -20°C. Avoid repeated freezing and thawing. |
| References | 1. Sato, S. Central control of bone remodeling by neuromedin U. Nature Medicine.;13(10):1234-40. 10/1/2007
2. Tai YT, Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis Blood. ;110(5):1656-63 9/1/2007 3. Huang, J. Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro. Life Sciences.;81(10):832-40. 8/16/2007 4. Irie, A. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone.;41(2):165-74. 8/1/2007 5. Hiraga, T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Research.;67(9):4157-63. 5/1/2007 6. Poubelle, P.E. Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Arthritis Research and Therapy.;9(2):R25 3/6/2007 7. Meadows, N.A. The expression of clcn7 and ostm1 in osteoclasts is coregulated by microphthalmia transcription factor. Journal of Biological Chemistry.;282(3):1891-904 1/19/2007 8. Hase H, TNF{alpha} mediates the skeletal effects of thyroid-stimulating hormone Proc Natl Acad Sci U S A. ;103(34):12849-54 8/22/2006 9. Yang M. Expression of and role for ovarian cancer G-protein-coupled receptor 1 (OGR1) during osteoclastogenesis. Journal of Biological Chemistry;281(33):23598-605. 8/18/2006 10. Lau YS Malignant melanoma and bone resorption. Br J Cancer.;94(10):1496-503 5/22/2006 11. Woo JT Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts Proc Natl Acad Sci U S A. ;103(12):4729-34 3/21/2006 12. Huang H Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL Cell Death Differ. 2006 Feb 24 2/24/2006 13. Muguruma, H. Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity. Clinical Cancer Research.;11(24 Pt 1):8822-8. 12/15/2005 14. van der Eerden BC The epithelial Ca2+ channel TRPV5 is essential for proper osteoclastic bone resorption Proc Natl Acad Sci U S A. ;102(48):17507-12 11/29/2005 |
